Titlebook: Chronic Myeloid Leukemia; Rüdiger Hehlmann Book 2021Latest edition The Editor(s) (if applicable) and The Author(s), under exclusive licens

adequate-intake

At-Risk Practices That No Longer Workh chronic myeloid leukemia (CML). There are currently five branded TKIs approved in the United States (US) and European Union (EU) for CML treatment, and one generic option (Gleevec’s generic, imatinib). Imatinib, a first-generation TKI, was the first treatment approved for CML by the European Medic

宽敞

Reflexive Practice for the Times We Live Ind to define time-related clinical milestones as well as eligibility for stopping treatment. To improve the comparability of molecular monitoring results between centers, an international scale (IS) for . measurement has been implemented by testing laboratories worldwide, either by the derivation of

Geyser

漂白

https://doi.org/10.1007/978-3-030-63875-7chronic myeloid leukemia (CML), contributing to the improvement of its management. During this period several tyrosine-kinase inhibitors (TKIs) have been developed, allowing most CML patients to reach survival similar to that of the general population. Disease phase classification has partially chan